We have developed and tested successfully a general method based on Cre-mediated recombination that can be used for ubiquitous or tissue-specific expression of protein products, including tumor-inducing oncoproteins. Depending on the specificity of a chosen promoter driving cre expression, tumors develop by design in bitransgenic mouse progeny derived by crossing Cre-producing mice with partners carrying a dormant oncogenic transgene (targeted into the 3 0 noncoding region of the cytoplasmic b-actin locus) that becomes functional after excision of a 'floxed' DNA segment. To provide proof-of-principle, we have used as models transgenes encoding the polyomavirus middle T antigen (PVMT) and the T antigens of the SV40 early region (SVER). Cre-dependent activation of widespread SVER expression resulted in hyperplasias or invasive tumors affecting particular visceral smooth muscles, whereas Cre-dependent, mammary gland-specific expression of PVMT-induced adenocarcinomas, according to plan. Unexpectedly, we also encountered spontaneous (Cre-independent) oncogene expression occurring as a rare event, which simulates the initiation of sporadic tumors and leads to PVMT-induced hemangiomas and mammary carcinomas or SVER-induced disseminated sarcomas, thus, revealing particular tissue susceptibilities to the actions of these oncoproteins.
Introduction
Genetically modified mice overexpressing oncogene products or lacking tumor suppressors are currently used as indispensable models in cancer research for the causal analysis of the combinatorial involvement of signaling effectors in deranged tumorigenic pathways, which promote deregulated proliferation, reduce apoptosis and potentially cause genomic instability.
Whereas the generation of germline mutations in tumor suppressor loci by gene knockout approaches is in principle straightforward, the development of transgenic strains for constitutive expression of cellular or viral oncogenes by using standard microinjection of DNA into fertilized eggs is an overall inefficient and time-consuming process, as several different transgenic lines must be analysed to identify those with desirable features. This drawback is due to random integration sites ('position effects') and/or differences in copy numbers affecting variably the level and tissue-specificity of transgene expression (reviewed by Palmiter and Brinster, 1986; Dorer, 1997) . Such problems can be potentially eliminated by a knockin approach using embryonic stem (ES) cells and blastocyst injections, to introduce single-copy transgenes, appropriately driven by tissue-specific promoters, into preselected and permissive genomic sites that can be disrupted without detrimental consequences (Bronson et al., 1996; Wallace et al., 2000; Srinivas et al., 2001) . We sought, however, to develop an alternate, general method that could serve the purposes already described and offer at the same time additional advantages, especially for studying tumorigenic processes. The principle of our scheme is the mating of mice of two engineered strains, one of which carries a dormant transgene that is inserted into a defined locus and is activated in the progeny of the cross by genetic elements present in the other strain. To develop this method, we used as models viral oncogenes. Variations of analogous principles have been previously used to remove transcriptional termination elements preventing the expression of either reporter transgenes or of specifically designed oncogenic loci (see, for example, Lakso et al., 1992; Mao et al., 1999; Jackson et al., 2001) .
Results and discussion

Experimental design
Our strategy is based on the cre/loxP site-specific recombination system, in which a recombinase (Cre) catalyses the excision of a DNA segment flanked ('floxed') by direct 34-bp loxP sites, and entails crosses between Cre-producing and Cre-responding mice. This binary system of genetically modified mice can be used for ubiquitous or tissue-specific expression of chosen proteins, including oncoproteins.
For studies on tumorigenesis, Cre-producers are mated with responder mice carrying a knockedin transgenic construct that includes a dormant oncogene. Production of the encoded oncoprotein is achieved in the progeny by Cre-mediated excision of a floxed segment located upstream from the oncogenic sequence. Thus, supply of active oncoprotein depends on the particular promoter driving cre expression which, by design, can occur either widely (in many or all tissues) or specifically in an individual tissue, resulting in the latter case in a 'designer' tumor.
As a location for a knockin insertion to generate Creresponder mice, we chose the 3 0 untranslated region (UTR) of the cytoplasmic b-actin gene (see Figure 1a ) that is expressed ubiquitously and at a higher level than any other protein (up to 5% of total protein in nonmuscle cells is b-actin, and this level is at least partially attained by a high transcriptional output). Placement of the insert 55 bases downstream from the termination codon leaves the coding region intact and also allows preservation of a 54-nucleotide sequence (the 'zipcode') that directs the cellular localization of b-actin mRNA (Kislauskis et al., 1994) . The key element of this design is to use the strong b-actin promoter for expression of a bicistronic mRNA, in which the transcripts of the actin gene and the inserted transgene would be physically linked. In the construct used for targeting (Figure 1a) , the 5 0 and 3 0 regions of homology to the actin locus are flanking a segment consisting of the following elements (placed in the same transcriptional orientation as that of the actin gene promoter). First, an internal ribosome entry site (IRES; 730 bp) of the murine encephalomyocarditis virus (EMCV) is used for cap-independent translation (see Kim et al., 1992; Mombaerts et al., 1996) of the neomycin resistance gene (neo), to select targeted ES cells. This selectable marker, linked to a polyadenylation signal (pA) derived from the bovine growth hormone gene, is flanked by loxP sites and is followed by a DNA sequence (usually a cDNA) encoding any chosen oncoprotein (or other protein) that is positioned between unique PacI and NotI sites. Owing to the presence of these rare restriction sites, the vector can serve as a cassette for cloning any cDNA of choice, after removal of a previous insert (for brevity, such derivatives are referred to below as 'actin cassettes'). The pA signal of the b-actin gene itself, which is located downstream from the inserted cDNA, can serve for transcript polyadenylation, in case the natural pA of the insert is not retained.
After successful targeting, and as long as the loxP sites remain unrecombined, a bicistronic message is formed from which actin is translated starting from its own AUG, while an initiation complex recognizes independently the first AUG downstream from the IRES and initiates translation of neo. Thus, colonies of targeted ES cells are selected on the basis of G418-resistance. Owing to the presence of a strong polyadenylation signal at the end of the neo cassette, the sequence encoding the oncoprotein is not represented in mature bicistronic mRNA and, even if present in some read-through transcripts, it cannot be translated. On the other hand, upon cre-mediated site-specific recombination (elimination of neo, leaving behind a single loxP site), the IRES element is juxtaposed to the transgenic cDNA, and the new bicistronic mRNA now encodes actin and also oncoprotein.
Application of the method
Using the strategy described above, we generated 'actin cassette' constructs containing several different sequences encoding signaling effectors or oncoproteins, including the polyomavirus middle T antigen (PVMT; Figure 1b ) and the SV40 T antigens (collectively referred to here as SV40 early region (SVER); Figure 1c ). The latter three proteins, large T (SVLT), small t and 17kT (Zerrahn et al., 1993) are products of mRNAs generated by alternate splicing from the SVER sequence that we have cloned (retaining the natural pA signals) into the actin cassette. We used SVER rather than SVLT alone by considering that SVLT is essential for cell transformation, while the other antigens stimulate its actions (the spectrum of tumors developing in transgenic mice expressing either SVER or only SVLT could be different; Choi et al., 1988; Ratineau et al., 2000) .
Prior to the generation of mice, targeted clones were tested successfully for activation of the dormant transgene by using transient expression of Cre to excise the neo gene (see, for example, Figure 1b , panel (i)). Western analysis was then used to demonstrate that the oncoproteins were translated efficiently, although their relative levels could not be assessed, due to the absence of an endogenous comparison standard. In another case, however, using a cassette carrying a cDNA for myristilated Akt1, Western analysis indicated that the level of protein produced from the exogenous sequence was Bfourfold higher than that of endogenous Akt1 ( Figure 1b , Akt Data; right panel). Nevertheless, this example cannot be indiscriminately extrapolated to other cases, as the level of steady-state transcripts appears to be unpredictably affected by the particular sequences of different inserts, which might perturb differentially the spatial relationships of hypothetical regulatory signals acting at the level of mRNA transcription and/or turnover (the b-actin 3 0 UTR includes some conserved sequences of unknown function). Overall, our limited observations indicate that the amount of mRNA from the intact actin locus is at least Bthreefold higher than that of the bicistronic transcript expressed from the unrecombined allele, whereas after Cre-mediated excision it can either remain at this level or decrease further both in an insert-dependent and tissue-dependent fashion (see, for example, Figure 1b , Akt Data; left panel). We note, however, that significant expression problems were not encountered in the cases of the two oncoprotein models presented here.
ES cells carrying the unrecombined version of each actin cassette were injected into C57BL/6J blastocysts and chimeras were generated, which transmitted the knockedin transgenes (Figure 1b, panel (ii) and c, panel (i) ). The performances of some of the actin-cassette transgenes, including PVMT and SVER, were tested successfully in mice, providing 'proof-of-principle' for the application of the method, as indicated in the following brief overview.
First, we attempted ubiquitous Cre-dependent excision of floxed DNA, to demonstrate that our method could be applied to transgene expression in all tissues, as a means of revealing particular tissue susceptibility to chosen oncoproteins. For this purpose, we used as Creproducers our Hs-cre1 transgenic mice (Dietrich et al., 2000) , which express constitutively in two-cell stage embryos a cre transgene driven by the Hsp70-1 heat shock promoter. We observed that expression of PVMT in early bitransgenic embryos resulted in lethality by e6.5 (data not shown), suggesting that the signaling pathways collectively deregulated by PVMT are indispensable for normal embryonic development. In contrast, analogous expression of SVER in bitransgenic progeny turned out to be compatible with viability, at least at the levels attained by the encoded oncoproteins. Interestingly, although neo excision occurred in all tissues, a tumorigenic phenotype that was manifested in B3-month-old animals was narrowly tissue specific. Thus, all females developed massive uterine leiomyosarcomas, whereas practically all males exhibited enormously enlarged seminal vesicles due to pronounced hyperplasia of the smooth muscle layers. In addition, because of smooth muscle hyperproliferation, marked dilation of the gallbladder was observed in animals of both sexes. These results are reported in detail elsewhere (Politi et al., 2004) , whereas below we describe the feasibility of inducing tissue-specific tumors using our system. Unexpectedly, we also encountered deletion of the neo sequence and consequent oncoprotein expression occurring without the involvement of Cre. Despite the very low frequency of such deletion events involving very few cells in the population (see below), the spontaneous activation of oncoprotein production affected all mice, which developed tumors apparently by clonal growth.
Tissue-specific Cre-dependent tumorigenesis
To provide proof-of-principle that our method could be applied to the generation of designer tumors, we sought to induce development of mammary adenocarcinomas by using the PVMT actin cassette. For this purpose, we crossed mice carrying the PVMT transgene with Wap cre/ þ producers (see Ludwig et al., 2001) , in which cre is expressed specifically in mammary epithelial cells during late pregnancy and lactation. From these matings, we generated and then monitored a cohort of 50 b-actin PVMT/ þ /Wap cre/ þ females. Of these mice, only 15 (30%) turned out to be informative for our purposes, as the remaining (mostly virgin animals) died or were killed prior to the appearance of breast tumors because of rapid development of spontaneous hemangiomas (Table 1 ; see next section, for a description of Creindependent tumorigenesis).
The 15 b-actin PVMT/ þ /Wap cre/ þ females, which underwent one or more pregnancies, developed polyclonal mammary tumors with a relatively short latency (only 50% of the animals remained tumor-free after 121 days; T 50 ¼ 121). In fact, considering that cre expression from the Wap locus commences late in gestation (Ludwig et al., 2001) , the development of tumors once PVMT became available was very rapid. Thus, assuming that tumor latency in this case was, in effect, the time between the birth of the first litter and the age at killing, the calculated T 50 is 33 days. The actual and calculated T 50 values are comparable to those reported for mammary tumors induced by PVMT transgenes driven by the MMTV LTR promoter that is already active in virgin animals (T 50 ¼ 53-82 days; Guy et al., 1992; Webster et al., 1998) . Moreover, the tumors appearing in b-actin PVMT/ þ /Wap cre/ þ and MMTV-PVMT animals exhibited practically indistinguishable features. They affected all of the mammary glands; they were palpable and hard; and, upon dissection, they appeared to lack nodules and to involve the entire gland. Their polyclonality was further demonstrated by histopathological analysis, which showed complete cellular transformation and absence of residual normal parenchyma. Microscopically, all of these tumors were intraductal and highly invasive adenocarcinomas extending to the underlying striated muscle. Invariably, there was evidence of myoepithelial proliferation. The epithelial component of the neoplasm consisted of medium to large size cells with pleomorphic, irregular and hyperchromatic nuclei and exhibited a papillary pattern of growth occurring within cystic spaces that were ultimately variably filled (Figure 2d ). In addition, squamous elements were observed in two of the cases.
At the molecular level, recombination was detected specifically in all of the mammary glands of b-actin PVMT/ þ /Wap cre/ þ mice, while PVMT was expressed exclusively in this tissue (Figure 1b , panels (iii) and (iv)), indicating that tissue-specific oncogene expression can indeed be achieved using the 'actin cassette'.
Considering that proof-of-principle is now available, our method can be refined to allow control of Figure 1 Application of a method for ubiquitous or tissue-specific expression of oncoproteins in mice. (a) Knockin approach to generate Creresponding transgenic mice carrying inactive oncogenes in the cytoplasmic b-actin locus shown on top (in the restriction map, the six exons of the actin gene are represented by black rectangles; the ATG initiation codon is present in exon 2). In the targeting vector ('actin cassette') shown next, a 5 0 region of homology (1.3 kb) extends between a PmeI site (Pm) located 0.27 kb upstream of exon 4 to an FspI site (F) present 50 bp downstream from the TAG terminator in exon 6. This segment is followed by the EMCV IRES (B0.7 kb; checkered rectangle) that is used for cap-independent translation of the neo selectable marker linked to a polyadenylation signal (pA) derived from the bovine growth hormone gene (1.1 kb; open rectangle). The 1.1 kb neo(pA) region is flanked by loxP sites (black triangles) and is followed by a gene (denoted in the diagram as 'Oncogene'; stippled rectangle) positioned between PacI (Pc) and NotI (N) sites. The 3 0 region of homology (5.0 kb) extends between the FspI site of exon 6 to an EcoRI (R) site located at a distance of 4.3 kb downstream from the pA signal of the b-actin gene. After successful targeting by homologous recombination in ES cells ('knockin'; indicated by X symbols), a bicistronic ('actin-neo') message is formed. Upon Cre-mediated neo excision a single loxP site is left behind and a new bicistronic mRNA ('actin-oncogene') is generated. The position of the probe (probe A) used for Southern analyses, and the sizes of the endogenous, targeted and recombined DNA fragments recognized by the probe are indicated. The additional restriction sites shown are: PstI (P) and SalI (S). (b) Molecular analyses of PVMT-induced tumorigenesis using the method described in panel a. For Southern analysis, DNA was digested with PacI and EcoRI. The data indicate: (i) Targeting of ES cells using an 'actin cassette' carrying PVMT (lane Tr; targeted) and in vitro excision of neo by Cre-mediated recombination (lane Rc; recombined). The size (11.1 kb) of the EcoRI fragment recognized by probe A that is derived from the intact b-actin allele is reduced to 8.2 kb in targeted ES cells (Tr) and to 7.0 kb after transient expression of cre in ES cells (Rc). (ii) Genotyping of tail DNA from mice that turned out to be wild-type (Wt) or heterozygotes carrying the PVMT transgene (Tg). (iii) Analysis of tail (Tl) and mammary tumor (Mt) DNA from a female animal with a b-actin PVMT/ þ ; Wap cre/ þ genotype. Cremediated recombination depending on Wap gene expression in the mammary gland has specifically occurred in the epithelial cells that gave rise to the tumor. (iv) For confirmation, protein extracts from a mammary tumor (Mt) and various tissues (lung (Lu), heart (He), kidney (Ki), liver (Li), brain (Br) and spleen (Sp)) of another female animal with a b-actin PVMT/ þ ; Wap cre/ þ genotype were assayed for the presence of PVMT by Western analysis using an anti-PVMT antibody after immunoprecipitation with a different anti-PVMT antibody (see Materials and methods). PVMT was detected exclusively in the extract from the tumor. Proteins extracted from targeted ES cells before (Tr) and after (Rc) neo excision by transiently expressed Cre were used, respectively, as negative and positive controls. (v) Genotyping of DNA extracted from tissues of a female animal carrying the PVMT sequence, but not a Cre-producing transgene. The results shown are for the tail (Tl), mammary glands (Mg), focal (Cre-independent) mammary tumor (Mt), and spleen (Sp). The 7.0 kb EcoRI/PacI fragment that is characteristic of neo excision, which occurred spontaneously in this case, appears only in the tumor sample. The ''Akt Data'' in panel b presents the results of Northern (left) and Western (right) analyses assaying the performance of an actin cassette carrying a cDNA for myristilated Akt1 in ES cells, to provide an example of the expression level attained by a protein that has an endogenous counterpart (comparison standard). Hybridization of the Northern blot with an actin probe indicates that, in comparison with the level of transcript from the intact actin allele, expression of the bicistronic RNA from the targeted locus was downregulated both before (Tr) and after (Rc) neo excision by transient expression of Cre (see also text). Nevertheless, the data of immunoblotting (Akt Data; right panel) demonstrated that on average (four independent assays) the level of protein derived from the transgene was 4.272.1-fold higher than that of endogenous Akt1. (c) Molecular analyses of SVER-induced tumorigenesis using the method described in panel a. For Southern analysis, DNA was digested with PstI. The results of genotyping using tail DNA from mice that turned out to be Wt or heterozygotes carrying the SVER transgene (Tg) are shown in (i). The Northen blot in (ii), which was hybridized with an SVLT probe, demonstrates specific expression of oncogenic RNA in a spontaneous thoracic tumor that appeared in an animal carrying the SVER sequence, but not a Cre-producing transgene, whereas a hybridization signal was not detected in unaffected tissues (same abbreviations as in panel b). (iii) DNA sequence analysis of cloned PCR amplification products from spontaneous (Cre-independent) SVER-induced undifferentiated sarcomas in the spleens of several animals revealed nonprecise deletions, except in sequence 1a, as shown in the diagram that compares the sequenced DNA samples (lines) with the structure of the targeted locus (the rectangles represent the loxP repeats, not in scale; for details, see text). Sequences 1a and 1b were from different clones of DNA amplified from the same spleen tumor Number of pregnancies before the appearance of tumors: 1 (n ¼ 9), 2 (n ¼ 4), 3 (n ¼ 1), 4 (n ¼ 1).
e Killed because of the development of mammary tumors that occurred 12-69 days after the first pregnancy (T 50 ¼ 33 days). Lung metatstases were noted in 9/15 cases. Hemangiomas were noted in 10/15 animals Conditional tumorigenesis in mice K Politi et al oncoprotein expression through the use of inducible systems for cre expression. Furthermore, development of similar cassettes involving additional host loci of highly and ubiquitously expressed genes would significantly expand the analytical power of the approach by allowing the generation of mice carrying various oncogene combinations through carefully designed breeding programs. For any cassette, the generation of a single line of mice carrying a transgenic oncogene of interest, which can be used with a variety of different activating strains, provides great experimental flexibility for dissecting with a combination of histopathological and expression profiling analyses the particular pathways variably cooperating with the aberrant signaling of an oncoprotein of interest at different anatomical sites.
Cre-independent excision of floxed DNA in mice
Previous results (Bautch et al., 1987; Williams et al., 1988) had demonstrated that endothelial cells are particularly sensitive to the action of PVMT. Nevertheless, it was surprising to observe against expectation that mice carrying the PVMT actin cassette, but lacking the cre transgene necessary for activation of oncoprotein production, developed hemangiomas at a very high frequency. Usually, these vascular tumors appeared as subcutaneous and often hemorrhaging masses of variable size that became rapidly evident at diverse and sometimes multiple sites. Histologically, they appear as spongiform structures consisting of dilated vessels filled with blood (cavernous hemangiomas; Figure 2a and b), which were occasionally associated with fibrotic elements (sclerosing hemangiomas). In mice that died of presumptive anemia due to bleeding or were killed when moribund, hemangiomas were also detected in one or more internal organs, most frequently in the lungs (Figure 2a and b) , although other soft tissues, such as the liver, the uterus, etc. were often involved.
The emergence of hemangiomas, eventually affecting all of the PVMT-carrying animals, was stochastic, but rapid. Thus, from a cohort of 105 mice of both sexes that were monitored, only 50% of the animals remained free of endothelial tumors after a period of 42 days (T 50 ¼ 42). Overall, B77% of the mice (81/105) died or were killed by the age of 4 months. Of the remaining 24 animals that survived beyond this age (they all died by 8 months), 2/12 males and 9/12 females developed other tumor types often accompanied by hemangiomas. One of the males (age of 125 days) developed a mammary adenofibroma exhibiting cellular atypia, while the other (age of 217 days) manifested a hemangiosarcoma of the lung potentially emerging from a hemangioma background.
Interestingly, nine females, which underwent two to five pregnancies, developed (at ages ranging between 124 and 242 days; T 50 ¼ 163 days) Cre-independent mammary adenocarcinomas. These tumors (Figure 2c ) were histopathologically virtually indistinguishable from the carcinomas appearing in b-actin PVMT/ þ /Wap cre/ þ females (Figure 2d ). Thus, they exhibited the same papillary/ cystic pattern, although neither significant intraductal neoplasia nor significant myoepithelial proliferation were evident. Also, in contrast to the polyclonal Creinduced tumors that appeared with a significantly shorter latency (T 50 ¼ 121 days; Po0.003), the spontaneous carcinomas were focal and involved a single gland per animal with one exception (two glands). In five of the nine cases, lung metastases of the mammary carcinomas were noted.
Tumorigenesis in the absence of a cre transgene was also observed in mice carrying the SVER actin cassette either in one of the b-actin alleles (n ¼ 50) or in both alleles (n ¼ 26). These animals, monitored for a period of B13 months, developed disseminated and highly invasive undifferentiated sarcomas, albeit with relatively long latency (T 50 ¼ 250 days; a difference in tumor latency was not observed between the two groups, since the probability that the infrequent activation of the oncoprotein could occur in both alleles of a single cell is infinitesimally small).
Although it was difficult to identify the primary site of tumor development, we observed that in the majority of cases both the spleen and liver were grossly enlarged. Frequently, tumors appeared in additional abdominal and/or thoracic organs. An example of Northern analysis (Figure 1c, panel (ii) ) demonstrates that SVER was expressed only in the spontaneous thoracic tumor that developed in a particular animal, but not in unaffected organs. All of the examined tumors (n ¼ 19) consisted of large mesenchymal cells with a spindle shape and eosinophilic cytoplasm, which formed little matrix and were usually arranged in a fascicular pattern (Figure 3a and c). Irregular growth patterns and necrotic areas were observed in the larger of these neoplasms. Such lesions, representing a progressed stage of the tumorigenic process, also exhibited extensive neovascularization, marked cellular pleomorphism and high mitotic activity (25 mitotic figures per high power field vs 9-12 in less pleomorphic areas), and slight variability in nuclear size. An epithelial or lymphoid origin for these tumors was excluded by immunophenotyping, as the results were negative for cytokeratin and CD3 or B220 markers. On the other hand, in addition to strong immunostaining for SVLT (Figure 3c , inset), the tumors were shown to be positive for smooth muscle a-actin (Figure 3c , inset) and vimentin (a mesenchymal tissue marker) and negative for desmin (an intermediate filament protein characteristic of muscle cells, which is absent from myofibroblasts; Darby et al., 1990; Eyden, 2001 ). On the basis of these results, we have classified these SVER-induced tumors as high-grade undifferentiated sarcomas with myofibroblastic features. The Cre-independent PVMT and SVER tumors were analysed further to ascertain whether a DNA deletion event had occurred resulting in oncogene activation by juxtaposing the IRES element to the transgene. First, 11 hemangiomas (from eight animals) and four mammary tumors (from three animals) were examined by PCR, using for DNA amplification a forward primer at the 3 0 end of the IRES sequence and a reverse primer at the 5 0 end of PVMT. This combination of primers would yield either a 1.5 kb product, if the cassette were intact, or a 420 bp product, if the neo sequence had been deleted. Our detection of an amplification product of 420 bp in all cases indicated the occurrence of a deletion event, which was verified by Southern analysis of DNA from a subset of the tumor specimens (Figure 1b, panel (v) ). DNA sequencing of the PCR products showed that in 10 of the 11 hemangioma cases and in all four mammary tumors the deletion of the floxed neo sequence was precise, mimicking a Cre-mediated event and leaving behind a single loxP site. In the remaining examined hemangioma, the deletion was less extensive (218 bp downstream from the 5 0 loxP site were retained, consisting of a linker (23 bp) and a truncated neo sequence starting 11 bp upstream from the ATG initiation codon).
We next examined Cre-independent DNA deletion events in seven mice with SVER-induced sarcomas by performing PCR analysis using primers in the IRES (forward) and SVER (reverse) sequences, which would amplify products of 1.8 and 0.7 kb before and after elimination of the neo gene, respectively. Consistent with the disseminated character of the tumors, deletion events were scored in DNA samples prepared from several organs of each animal. The PCR products from spleen DNA were then cloned and independent isolates for each of the seven cases were sequenced. We found that, in contrast to the cases of spontaneous PVMTinduced hemangiomas and mammary tumors, the deletions, with one exception, were not precise in SVER sarcomas. The deleted regions (Figure 1c, panel (iii) ) varied in length and included one or both of the loxP sites and short stretches of adjacent sequences. On occasion, a portion of a loxP site was left behind, as was the case with a particular spleen specimen, which differed from the remaining samples because sequencing of DNA from a second, independent colony revealed a precise deletion configuration (a single loxP site had remained intact as observed in PVMT-induced tumors). The two deletion patterns detected in a single sarcoma cannot possibly correspond to independent events that occurred initially in different cells and were followed by separate clonal growth because the incidence of deletions is extremely low. From preliminary PCR-based experiments (not shown), we roughly estimate that the frequency of occurrence of deletion events, which could vary between tissue types, is lower than 1 per million cells, consistent with previous reports (Seperack et al., 1988; Hollies et al., 2001) . We think, therefore, that our observations are most compatible with the interpretation that precise excisions occur first and are followed by secondary microdeletions during tumor evolution. Such secondary alterations may be selected because they bring the SVER initiation codon closer to the IRES, thus, improving translatability and increasing advantageously the levels of the oncoproteins. Probably, analogous secondary deletions were not detected in spontaneous PVMT tumors because of significantly shorter latencies. Although we did not investigate the molecular mechanism underlying Cre-independent deletions, we note that they can be accounted for by replication and/ or recombination-dependent processes involving direct repeats, each consisting of a loxP site (34 bp) and flanking linker sequences (total of 22 bp). Thus, deletions can be generated during DNA replication by slipped mispairing between these repeats (see, for example, Efstratiadis et al., 1980) . Whereas the short length of the repeats (56 bp) is in accord with the replication model, the observed precision of the deletion process is more compatible with any one of several recombination-based mechanisms, such as unequal sister-chromatid exchange, gene conversion, intrachromatid recombination and single-strand annealing (Thomas and Rothstein, 1989) .
Previously, a transgenic design based on the occurrence of spontaneous DNA deletions in somatic mouse cells resulted in activation of Kras2 oncogene expression leading to tumorigenesis, but the length of direct repeats was much larger than in our case (7 kb; Johnson et al., 2001) . To some extent, such models, including ours, are mimicking processes occurring in sporadic cancer, because an infrequent event in a single cell initiates an oncogenic process by clonal expansion. In fact, in our experiments, Cre-independent DNA excisions became detectable in the first place from their consequences that led to clonal growth. As spontaneous deletions presumably emerge in many different cell types, but tumors develop only at sensitive anatomical sites, insights can be gained from the model organisms concerning the specificity of the tumorigenic pathways that are perturbed by defined oncogenic stimuli.
Assuming that deletions of DNA sequence flanked by direct repeats as short as 56 bp are a common occurrence in the genome, it is likely that they constitute a major mutational mechanism contributing to tumorigenesis. In this regard, different retroposition events constantly occurring in different somatic cells could randomly create direct repeats through the insertion of new elements in the vicinity of older family members. Such situations, which have been fortuitously simulated by the loxP sites in our constructs, could result in rare deletions that take place in only a few cells and lead to the first step of inactivation of tumor suppressor genes by removing exons or positive regulatory elements, or to activation of proto-oncogenes by truncation or removal of negative control sequences. Interestingly, active retroposons are much more abundant in the mouse than in the human genome (Lander et al., 2001) and this observation may turn out to be relevant to the eventual resolution of the paradox that the same type of tumor developing in rodents within 1-2 years requires 40-80 years in human (discussed by Barrett and Wiseman, 1992) .
Although sporadic tumors represent 490% of all human cancer cases, advancements in related mouse modeling are quite scarce (Berns, 2001; Johnson et al., 2001) . Therefore, the development of spontaneous (Cre-independent) tumors is a particularly useful feature of our system, as it can reveal the susceptibility of particular tissues to different initiating oncogenes, while other tissues remain unaffected, and has the potential to probe the open question of the mechanisms involved in the tissue-specific development of sporadic cancer.
Materials and methods
Mice
In addition to the transgenic mice generated specifically for developing the method that we have described, we used two available cre-expressing strains of mice, Hs-cre1 (Dietrich et al., 2000) and Wap cre/ þ (Ludwig et al., 2001) . Mice expressing a PVMT transgene in mammary glands under the direction of the MMTV LTR promoter (Guy et al., 1992) were obtained from the Jackson Laboratories.
Construction of targeting vectors
The rationale of including particular components in the targeting vectors is described in Results, while further details about their construction, outlined below, can be found in the legend to Figure 1 . An 11.0 kb EcoRI fragment containing all six exons of the cytoplasmic b-actin gene (Elder et al., 1988) was isolated from a genomic clone (provided by the laboratory of Dr Michael Getz) and used for constructing a targeting vector cassette ('actin cassette') in several steps. The final construct (Figure 1a ) consisted of 5 0 and 3 0 regions of actin locus homology flanking an IRES element, a promotorless neo gene, and a cDNA encoding PVMT. The neo cassette was flanked by loxP sites. In one of its orientations, the central region of a loxP site (conventional) upper strand contains two ATG triplets (5 0 ATGTATG3 0 ) that can affect the proper translatability of the second member of the bicistronic mRNA before or after Cre-mediated recombination. Accordingly, the opposite orientation (devoid of ATG triplets on the messagesynonymous strand) was chosen for positioning of the loxP sites in the actin cassette.
The PVMT cDNA (Treisman et al., 1981) was modified to possess an ATG initiator in a eukaryotic (Kozak) translational context and further modified to acquire 5 0 PacI and 3 0 NotI sites. The derivative (1.4 kb) was then cloned into unique PacI and NotI sites engineered after the second loxP site. To construct a targeting vector containing the SVER, the PVMT sequence (excised by PacI and NotI digestion) was replaced with a 2.65 kb AvrII/BamHI fragment of the SV40 genome from plasmid pSV2G (Floros et al., 1981 ; provided by Dr James Manley) that had been modified to acquire PacI and NotI site ends.
For each round of targeting, linearized vector was introduced into W9.5 ES cells by electroporation and, after drug selection, DNA of resistant clones was analysed by Southern blotting using as a probe a 0.9 kb NcoI fragment lying on genomic DNA upstream from the sequence represented in the targeting vector (probe A, see Figure 1a ). Owing to the use of a promotorless antibiotic-resistance gene, the targeting efficiency was very high. Thus, in nine independent targeting experiments (using eight different constructs), 65% (145/225) of the G418-resistant colonies were successfully targeted on average, ranging from 27% (16/59) to 100% (5/5; observed three times). Chimeras were generated by standard methods.
Molecular analyses
To ascertain before generating mice whether Cre-mediated recombination would be successful, targeted ES cells were Northern analysis was performed using total RNA (10 mg per lane) that was extracted from tissues with TRIzol reagent (Invitrogen). The blots were hybridized with probes recognizing the sequences encoding SVLT or b-actin.
For protein analysis, immunoprecipitation and immunoblotting were performed by standard procedures. To assay for PVMT, 1.5 mg of tissue protein extract was immunoprecipitated with PAb 762 mouse monoclonal antibody (provided by Dr S Dilworth) followed by immunoblotting using a rat ascites antibody to the polyomavirus T antigens (A5; provided by Drs T Benjamin and J Dahl). The antibody used for Western analysis of Akt1 expression was from Cell Signaling Technology.
Histological analysis
Mice exhibiting overt pathological signs were killed and all major organs were processed for histology. Paraffin blocks were sectioned and stained with hematoxylin and eosin. Immunophenotyping was performed according to standard procedures using primary antibodies against SVLT (DP02; Oncogene Research Products), cytokeratin (Chemicon), vimentin (RDI), CD3 (DAKO), B220 (Pharmingen), smooth muscle actin (DAKO) and desmin (DAKO).
